Non-contrast Enhanced Cardiac Magnetic Resonance Normal Values and Imaging Protocols (CMR-TECH)

November 1, 2023 updated by: Ursula Reiter, Medical University of Graz

Optimization of Non-contrast Enhanced 1.5 Tesla and 3 Tesla Cardiac Magnetic Resonance Imaging Techniques and Acquisition of Normal Values

One of the main problems in cardiac magnetic resonance (MR) investigations is the strong dependence of the achieved image quality on optimal settings of sequence parameters and anatomical and physiological situations and it is well known that the diagnostic impact of cardiac MR investigations crucially depends on the adaption of imaging protocols to patients' state and ability to cooperate.

The aim of the present study is the evaluation and optimization of various 1.5 Tesla and 3 Tesla cardiac MR investigation protocols without application of contrast agent as well as the acquisition of normal values for new cardiac MR images techniques:

  • normal myocardial morphology: T1-, T2- and T2*-weighted imaging and acquisition of normal values of magnetic relaxation times (sequence- and protocol dependent),
  • normal cardiac function: systolic and diastolic function (sequence- and protocol dependent),
  • cardiac anatomy and coronary artery imaging: feasibility to evaluate length, diameter and blood flow (sequence- and protocol dependent),
  • normal blood flow topologies in the heart and the surrounding great vessels: 2D- and 3D blood flow imaging and evaluation techniques (sequence- and protocol dependent).

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Austria
    • Styria
      • Graz, Styria, Austria, 8036
        • Recruiting
        • Medical Unitersity Graz, Department of Radiology, Division of General Radiology
        • Contact:
        • Contact:
        • Principal Investigator:
          • Ursula Reiter, PD DI Dr.
        • Sub-Investigator:
          • Gert Reiter, PD DI Dr.
        • Sub-Investigator:
          • Clemens Reiter, Dr.
        • Sub-Investigator:
          • Corina Kräuter, DI
        • Sub-Investigator:
          • Michael Fuchsjäger, Prof. Dr.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

healthy volunteers

Description

Inclusion Criteria:

  • No history of cardiac or pulmonary diseases
  • ability to give informed consent

Exclusion Criteria:

  • General MR exclusion criteria eg. patients with metal devices or other magnetic material in or on the subjects body which will be hazardous for MR investigation (e.g. heart pace-maker, brain aneurysm clip, nerve stimulators, electrodes, penile implants, coloured contact lenses, patch to deliver medications through the skin, any metal implants as rods, joints, plates, pins, screws, nails or clips, embolization coil, or any metal fragments or shrapnel in the body),
  • pregnancy,
  • claustrophobia.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
healthy volunteers
MR compliant volunteers with no history of cardiovascular diseases

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
cardiac volumes
Time Frame: up to 1 week
volumes of cardiac chambers in the cardiac cycle [ml], sequence- and protocol dependent
up to 1 week
cardiac performance
Time Frame: up to 1 week
ejection fraction of cardiac chambers [%], sequence- and protocol dependent
up to 1 week
cardiac muscle mass
Time Frame: up to 1 week
systolic and end-diastolic mass of cardiac chambers [g], sequence- and protocol dependent
up to 1 week
coronary artery anatomy
Time Frame: up to 1 week
length and diameter [mm], sequence-, and protocol dependent
up to 1 week
blood flow velocity
Time Frame: up to 1 week
maximum, minimum and average velocity [cm/s], sequence-, and protocol dependent
up to 1 week
blood flow vorticity
Time Frame: up to 1 week
number of vortices of blood flow in the heart and surrounding great vessels, sequence and protocol dependent
up to 1 week
blood flow timing
Time Frame: up to 1 week
time points of characteristic blood flow patterns in the heart and surrounding great vessels in the cardiac cycle [ms], sequence-, and protocol dependent
up to 1 week
magnetic relaxation times
Time Frame: up to 1 week
systolic and diastolic T1, T2, T2* [ms], sequence- and protocol dependent
up to 1 week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Medical University of Graz

Collaborators

Amt der Steiermärkischen Landesregierung, Abteilung 3

Investigators

  • Principal Investigator: Ursula Reiter, PhD, Medical Unitersity Graz, Department of Radiology, Division of General Radiology

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2011

Primary Completion (Estimated)

December 1, 2025

Study Completion (Estimated)

December 1, 2027

Study Registration Dates

First Submitted

November 3, 2012

First Submitted That Met QC Criteria

November 13, 2012

First Posted (Estimated)

November 20, 2012

Study Record Updates

Last Update Posted (Estimated)

November 3, 2023

Last Update Submitted That Met QC Criteria

November 1, 2023

Last Verified

November 1, 2023

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • CMR-12-TECH-02

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe